Beneficial effect of crotamine in the treatment of myasthenic rats

Muscle and Nerve

Volumn 47, Issue 4, 2013, Pages 591-593

  Hernandez Oliveira e Silva, Saraguaci ^a   Rostelato Ferreira, Sandro ^a   Rocha e Silva, Thomaz Augusto Alves ^a   Randazzo Moura, Priscila ^a   Dal Belo, Cháriston André ^b   Sanchez, Eladio Flores ^c   Borja Oliveira, Caroline R ^d   Rodrigues Simioni, Léa ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

^c FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Crotamine; Myasthenia gravis; Myasthenic rats; Neostigmine; Skeletal muscle

Indexed keywords

CROTAMINE; NEOSTIGMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTROMYOGRAPHY; EXERCISE TOLERANCE; FACILITATION; FATIGUE; MALE; MUSCLE FUNCTION; MUSCLE TWITCH; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREADMILL EXERCISE;

ANIMALS; CHOLINESTERASE INHIBITORS; CROTALID VENOMS; DRUG EVALUATION, PRECLINICAL; ELECTROMYOGRAPHY; EXERCISE TOLERANCE; HINDLIMB; MALE; MUSCLE, SKELETAL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEOSTIGMINE; NEUROMUSCULAR JUNCTION; RATS; RATS, INBRED LEW; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 84875602907     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23714     Document Type: Article

References (29)

1. Dierdorf SF, Walton S. Anesthesia for patients with rare and coexisting diseases. In: Barash PG, Cullen BF, Soelting RK, editors. Clinic anesthesia, 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. 502 p.
2. Argov Z. Management of myasthenic conditions: nonimmune issues. Curr Opin Neurol 2009;22:493-497.
3. Qian-Sheng Y, Harold WH, Weiming L, Debomoy KL, Arnold B, Nigel H. Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem 2010;18:4687-4693.
4. Barrio A, Vital Brazil O. Neuromuscular action of the Crotalus terrificus terrificus poisons. Acta Physiol Latinoam 1951;1:291-308.
5. Gonçalves JM, Polson A. The electrophoretic analysis of snake venoms. Arch Biochem 1947;13:253-259.
6. Gonçalves JM. Estudos sobre venenos de serpentes brasileiras. II-Crotalus terrificus crotaminicus, subespécie biológica. Ann Acad Bras Ci{ring in equal to}nc 1956;28:365-367.
7. Rádis-Baptista G, Kerkis I. Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties. Curr Pharm Des 2011;17:4351-4361.
8. Ownby CL. Structure, function and biophysical aspects of the myotoxins from snake venoms. J Toxicol Toxin Rev 1998;17:213-238.
9. Vital Brazil O, Prado-Franceschi J, Laure CJ. Repetitive muscle responses induced by crotamine. Toxicon 1979;17:61-69.
10. Matavel ACS, Ferreira-Alves DL, Beirão PSL, Cruz JS. Tension generation and increase of voltage-activated sodium current by crotamine. Eur J Pharmacol 1998;348:167-173.
11. Vital Brazil O, Fontana MD. Toxins as tools in the study of sodium channel distribution in the muscle fiber membrane. Toxicon 1993;31:1085-1098.
12. Chang CC, Tseng KH. Effect of crotamine, a toxin of South American rattlesnake venom, on the sodium channel of murine skeletal muscle. Br J Pharmacol 1978;63:551-559.
13. Camillo MAP, Arruda Paes PC, Troncone LRP, Rogero JR. Gyroxin fails to modify in vitro release of labeled dopamine and acetylcholine from rat and mouse striatal tissue. Toxicon 2001;39:843-853.
14. Kawanami S, Mori S. Experimental autoimmune myasthenia gravis induced by thymic acetylcholine receptor-like protein. Fukuoka Igaku Zasshi 1994;85:120-127.
15. Dal Belo CA, Leite GB, Fontana MD, Corrado AP, Zanandréa Baso AC, et al. New evidence for a presynaptic action of prednisolone at neuromuscular junction. Muscle Nerve 2002;26:37-43.
16. Brown GL. The neuromuscular junction. J Physiol 1938;92:22.
17. Priviero F, De Nucci G, Antunes E, Zanesco A. Negative chronotropic response to adenosine receptor stimulation in rat right atria after run training. Clin Exp Pharmacol Physiol 2004;31:741-743.
18. Pourmand R. Myasthenia gravis. Dis Mon 1997;43:65-109.
19. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski F, et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998;163:89-120.
20. Serra A, Ruff R, Kaminski H, Leigh JR. Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles. Ann NY Acad Sci 2011;1233:26-33.
21. Pritchard EAB. The use of "Prostigmin" in the treatment of myasthenia gravis. Lancet 1935;1:432-434.
22. Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303-307.
23. Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2011;16:CD006986.
24. Mantegazza R, Bonanno S, Camera G, Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat 2011;7:151-160.
25. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003;61:1652-1661.
26. Toyama MH, Marangoni S, Novello JC, Leite GB, Prado-Franceschi J, da Cruz-Höfling MA, et al. Biophysical, histopathological and pharmacological characterization of crotamine isoforms F22 and F32. Toxicon 2003;41:493-500.
27. Ponce-Soto LA, Martins-de-Souza D, Novello JC, Marangoni S. Structural and biological characterization of two crotamine isoforms IV-2 and IV-3 isolated from the Crotalus durissus cumanensis venom. Protein J 2007;26:533-540.
28. Ponce-Soto LA, Martins-de-Souza D, Marangoni S. Structural and pharmacological characterization of the crotamine isoforms III-4 (MYX4-CROCu) and III-7 (MYX7-CROCu) isolated from the Crotalus durissus cumanensis venom. Toxicon 2010;55:1443-1452.
29. Slater CR. Structural factors influencing the efficacy of neuromuscular transmission. Ann NY Acad Sci 2008;1132:1-12.